XML 22 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue (Notes)
3 Months Ended
Mar. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer
REVENUE
The following table presents the Company’s revenues disaggregated by geographical region and revenue type for the three-month period ended March 30, 2018 ($ in millions). Sales taxes and other usage-based taxes are excluded from revenues. The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which includes Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not high-growth markets.
 
Life Sciences
 
Diagnostics
 
Dental
 
Environmental & Applied Solutions
 
Total
Geographical region:
 
 
 
 
 
 
 
 
 
North America
$
480.4

 
$
607.4

 
$
291.3

 
$
418.3

 
$
1,797.4

Western Europe
449.9

 
310.4

 
175.6

 
264.8

 
1,200.7

Other developed markets
144.9

 
92.2

 
43.9

 
31.6

 
312.6

High-growth markets
400.8

 
509.7

 
161.8

 
312.4

 
1,384.7

Total
$
1,476.0

 
$
1,519.7

 
$
672.6

 
$
1,027.1

 
$
4,695.4

 
 
 
 
 
 
 
 
 
 
Revenue type:
 
 
 
 
 
 
 
 
 
Recurring
$
970.4

 
$
1,308.5

 
$
488.0

 
$
557.0

 
$
3,323.9

Nonrecurring
505.6

 
211.2

 
184.6

 
470.1

 
1,371.5

Total
$
1,476.0

 
$
1,519.7

 
$
672.6

 
$
1,027.1

 
$
4,695.4


The Company sells equipment to customers as well as consumables, spare parts, software licenses and services that customers purchase on a recurring basis. Consumables are typically critical to the use of the equipment and are used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation and purification processes, and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as dental implants and water treatment solutions. The Company separates its goods and services between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services, spare parts, software licenses recognized over time, SaaS, sales-and-usage based royalties and OTLs. Nonrecurring revenue includes sales from equipment, software licenses recognized at a point in time and STLs. OTLs and STLs are included in the above revenue amounts. For the three-month period ended March 30, 2018, revenue accounted for under Topic 840, Leases was $97 million.
Remaining Performance Obligations
Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term consumable supply arrangements, extended warranty, service and PCS contracts, SaaS and other long-term contracts. Remaining performance obligations do not include revenue from contracts with customers with an original term of one year or less, revenue from long-term consumable supply arrangements with no minimum purchase requirements or revenue expected from purchases made in excess of the minimum purchase requirements or revenue from equipment leased to customers. While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote. Additionally, the Company has elected to exclude contracts with customers with an original term of one year or less from remaining performance obligations while these contracts are included within backlog.
As of March 30, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $1.7 billion. The Company expects to recognize revenue on approximately 72% of the remaining performance obligations over the next 24 months, 44% recognized in the first 12 months and 28% recognized over the subsequent 12 months, and the remainder recognized thereafter.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Consolidated Condensed Balance Sheets. In addition, the Company defers certain costs incurred to obtain a contract (contract costs).
Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Condensed Balance Sheet. The balance of contract assets as of March 30, 2018 and at the date of adoption of ASC 606 were $94 million and $114 million, respectively.
Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Condensed Balance Sheet based on the timing of when the Company expects to recognize revenue. As of March 30, 2018 and at the date of adoption of ASC 606, contract liabilities were $801 million and $783 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheet. The increase in the contract liability balance during the three-month period ended March 30, 2018 is primarily as a result of cash payments received in advance of satisfying performance obligations and foreign currency exchange, offset by $265 million of revenue recognized during the period that was included in the contract liability balance at the date of adoption.
Contract costs—The Company capitalizes certain direct incremental costs incurred to obtain a contract, typically sales-related commissions, where the recognition period for the related revenue is greater than one year. These costs are amortized over the contract term or a longer period, generally the expected life of the customer relationship if renewals are expected and the renewal commission is not commensurate with the initial commission. Contract costs are classified as current or long-term other assets in the Consolidated Condensed Balance Sheet based on the timing of when the Company expects to recognize the expense and are generally amortized into earnings on a straight-line basis (which is consistent with the transfer of control for the related goods or services). Management assesses these costs for impairment at least quarterly and as “triggering” events occur that indicate it is more likely than not that an impairment exists. The balance of contract costs as of March 30, 2018 and at the date of adoption were not significant. Amortization expense for the three-month period ended March 30, 2018, was also not significant. The costs to obtain a contract where the amortization period for the related asset is one year or less are expensed as incurred and recorded within selling, general and administrative expenses in the accompanying Consolidated Condensed Statement of Earnings.
Contract assets, liabilities and costs are reported on the accompanying Consolidated Condensed Balance Sheet on a contract-by-contract basis.